CD8A and hepatocellular carcinoma: The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in HCC has been reported by our group (Shang et al, 2004), and our application for clinical trial of NY-ESO-1b peptide vaccine for the immunotherapy in HCC patients is under way.